Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tamir Biotechnology (formerly Alfacell Corporation) said that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three of the company's compounds Onconase (Ranpirnase), Natural P31 and Recombinant Amphinase 2 showed in vitro results rarely seen before by the US government for the dengue virus.
Subscribe to our email newsletter
NIAID used a Selectivity Index (SI) to determine the effectiveness of a compound. The SI measures EC50 (50% virus-inhibitory (effective) concentration and EC90 (90%) cell inhibitory (cytotoxic) concentration determined in stationary cells.
The SI scores for the three compounds tested for dengue virus range from 110-130. According to the scientists who conducted the testing, rarely have they seen an SI above 10.
Charles Muniz, CEO of Tamir Biotechnology, said: “Due to these compelling results, the government has informed us they will be conducting studies in dengue animal models in the near future.
“This study expands the use of our compounds against other viruses and other life threatening diseases with the possibility of development of a new class of therapies. We intend to use all resources that are available to us by the government for discovering other viral targets for our compounds.”